Author:
Li Tian-yu,Su Wei,Li Liang-liang,Zhao Xiao-guang,Yang Na,Gai Jia-xin,Lv Xin,Zhang Jing,Huang Meng-qin,Zhang Qing,Ji Wei-hang,Song Xiao-ying,Zhou Yu-hong,Li Xue-lian,Shan Hong-li,Liang Hai-hai
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference30 articles.
1. Hinderer S, Schenke-Layland K. Cardiac fibrosis—a short review of causes and therapeutic strategies. Adv Drug Deliv Rev. 2019;146:77–82.
2. Passaro F, Tocchetti CG, Spinetti G, Paudice F, Ambrosone L, Costagliola C, et al. Targeting fibrosis in the failing heart with nanoparticles. Adv Drug Deliv Rev. 2021;174:461–81.
3. Tao YK, Zhao SP, Yu PL, Shi J, Gu CD, Sun HT, et al. Elevated platelet activating factor level in ischemia-related arrhythmia and its electrophysiological effect on myocardium. Biomed Environ Sci. 2013;26:365–70.
4. Zheng GH, Xiong SQ, Mei LJ, Chen HY, Wang T, Chu JF. Elevated plasma platelet activating factor, platelet activating factor acetylhydrolase levels and risk of coronary heart disease or blood stasis syndrome of coronary heart disease in Chinese: a case control study: a case-control study. Inflammation. 2012;35:1419–28.
5. Penna C, Bassino E, Alloatti G. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp Biol Med. 2011;236:390–401.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献